CPC A61K 48/0041 (2013.01) [A61K 9/107 (2013.01); A61K 31/282 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 47/10 (2013.01); A61K 47/34 (2013.01); A61K 47/60 (2017.08); A61K 47/646 (2017.08); A61K 47/6907 (2017.08); A61K 47/6935 (2017.08); A61K 48/005 (2013.01); C07K 2/00 (2013.01); C08G 69/10 (2013.01); C08G 81/00 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/90 (2013.01); A61K 2039/585 (2013.01); C12N 15/09 (2013.01); C12N 2310/20 (2017.05); G01N 21/47 (2013.01)] | 28 Claims |
1. A composition comprising:
an agent, wherein the agent is (a) a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger, or (b) a nucleic acid encoding a nuclease selected from the group consisting of Cas9, TALEN, and zinc finger;
an optional pharmaceutically acceptable carrier;
an optional DNA editing template; and
a block copolymer comprising:
(i) a first block comprising a plurality of first monomers, wherein each first monomer is hydrophilic;
(ii) a second block comprising a plurality of second monomers, wherein each second monomer has the structure of Formula II:
wherein R2 is C1-C6alkyl, C3-C6alkenyl, C5-C22carbocyclyl-substituted C1-C6alkyl, or 5-22-membered heterocyclyl-substituted C1-C6alkyl; and
(iii) a third block comprising a plurality of third monomers, wherein each third monomer is positively charged at a pH from about 6.8 to about 7.4,
wherein
the agent is non-covalently associated with the block copolymer; and
the DNA editing template, when present, is non-covalently associated with the block copolymer.
|